Citalopram and Stress Reactivity

Depression Clinical Trial

Official title:

The Effect of Acute Citalopram on Response to Acute Stress Induction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04161209
• Other study ID #: OCST_Citalopram
• Status: Recruiting
• Phase: N/A
• Start date: October 11, 2019
• Est. completion date: September 2020

Study information

• Verified date: November 2019
• Source: University of Oxford
• Contact: Susannah Murphy, DPhil
• Phone: 01865 618313
• Email: susannah.murphy[@]psych.ox.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is investigating whether acute administration of citalopram is associated with a decrease in stress reactivity in healthy volunteers, compared to placebo administration. Using a parallel-group double-blind design, participants will be randomised to receive either an acute dose of citalopram or placebo. All participants will have come in for a screening visit. On the day of the research visit (following drug administration) participants will have completed a number of widely used computer-based cognitive tasks measuring emotional processing biases. They will then complete the Oxford Cognition Stress Task, a web-based acute stress induction paradigm, which is designed to induce mild transient increases in stress and arousal. Identifying early changes in stress reactivity following antidepressant treatment will increase the investigator's knowledge of how antidepressants operate, and provide putative targets to identify early response to antidepressants.

Description:

In the Oxford Cognition Stress Task (OCST), participants are presented with a series of mental arithmetic, verbal (anagrams) and visuospatial (visual search) challenges on a computer screen. There is a time limit for completing each challenge, which is displayed on the screen as a time bar. To induce a high failure rate, the timing and difficulty of the challenges is automatically varied to ensure participants are correctly complete only 20-40% of the challenges within the time, and some of the verbal challenges (anagrams) are impossible to solve. Participants are given feedback on their performance on the screen which indicates that they are performing badly. Heart rate will be measured continuously during the OCST, and during pre- and post- task periods. Baseline and post-OCST measures of blood pressure and samples of saliva (for cortisol analysis) will be taken. Participants will also complete Visual Analogue Scales pre- and post-OCST to give a subjective measure of stress and mood. Participants will not be told the extent to which becoming stressed (and finding the task difficult) is intended. At the end of the test session, participants will be fully debriefed as to the nature of the OCST.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male or Female

• Aged 18 -45 years

• Fluent in written and spoken English at a sufficient level to understand and complete the tasks

• Body Mass Index (BMI) 18-30

• Participant is willing and able to give informed consent for participation in the study

• Not currently taking any regular medications (expect the contraceptive pill)

Exclusion Criteria:

• Any past or current Axis 1 DSM-V psychiatric disorder

• Current use of psychoactive medication (except the contraceptive pill, the Depo-Provera injection or the progesterone implant) or medication which may affect the stress response (e.g. corticosteroids, beta-blockers)

• Current or past history of drug or alcohol dependency

• History of current significant neurological condition (e.g. epilepsy) or heart disease/hypertension

• Known hypersensitivity to the study drug

• Currently pregnant or breast feeding

• Previous participation in a study that uses the same or similar computer tasks as those used in the present study

• Previous participation in a study that involves the use of a medication within the last three months

• Significant medical condition

• Smokers consuming > 5 cigarettes per day

• Individuals consuming > 6 caffeinated drinks per day

• Lactose Intolerance (due to the study involving administration of a lactose placebo tablet)

Related Conditions & MeSH terms

• Antidepressive Agents
• Cognition
• Depression
• Depressive Disorder
• Disease
• Mental Disorder
• Mental Disorders
• Stress

Intervention

Drug:
• Citalopram
Single dose administration of citalopram (20mg)

Other:
• Placebo
Lactose placebo tablet

Locations

Country	Name	City	State
United Kingdom	University of Oxford	Oxford

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	University of Bath

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Heart rate (beats per minute)	Difference in heart rate during the Oxford Cognition Stress Task relative to pre-task baseline period between citalopram and placebo groups	Day 1: 4.5-5.5 hours post drug administration
Secondary	Heart rate variability (Root Mean Square Of Successive Differences: RMSSD)	Difference in RMSSD during the Oxford Cognition Stress Task relative to pre-task baseline period between citalopram and placebo groups	Day 1: 4.5-5.5 hours post drug administration
Secondary	Salivary cortisol	Difference in salivary cortisol following the Oxford Cognition Stress Task relative to pre-task baseline between citalopram and placebo groups; difference in area under the curve for all study timepoints between citalopram and placebo groups	Day 1: 4.5-5.5 hours post drug administration
Secondary	Blood pressure	Difference in systolic and diastolic blood pressure following the Oxford Cognition Stress Task relative to pre-task baseline between citalopram and placebo groups	Day 1: 4.5-5.5 hours post drug administration
Secondary	Subjective measures of stress and arousal	Difference in state anxiety, positive and negative affect, and Visual Analogue Scale (VAS) ratings of stress (from 0 to 100, where 0 indicates 'Not at all' and 100 indicates 'Extremely') following the Oxford Cognition Stress Task relative to pre-task baseline between citalopram and placebo groups	Day 1: 4.5-5.5 hours post drug administration

External Links

•   PERL Oxford webpage